Managing adverse effects and drug-drug interactions of antiplatelet agents (Q37930967)

25 August 2017

1 reference

title

Managing adverse effects and drug-drug interactions of antiplatelet agents (English)

1 reference

25 August 2017

0 references

2

A Michael Lincoff

1 reference

25 August 2017

Arun Kalyanasundaram

1

1 reference

25 August 2017

Medscape

series ordinal

3

1 reference

25 August 2017

language of work or name

English

0 references

publication date

13 September 2011

1 reference

Nature Reviews Cardiology

25 August 2017

published in

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

592-600

1 reference

Thrombotic thrombocytopenic purpura associated with clopidogrel

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Intensifying platelet inhibition--navigating between Scylla and Charybdis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clinical aspects of platelet inhibitors and thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Retroperitoneal hematoma after percutaneous coronary intervention: prevalence, risk factors, management, outcomes, and predictors of mortality: a report from the BMC2 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Aspirin, warfarin and a thienopyridine for acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Massive nasal bleeding and hemodynamic instability associated with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Images in cardiovascular medicine. Carotid plaque reduction after medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Heparin-Induced Thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function — a flow cytometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Prevalence of comorbidity of chronic diseases in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.128

Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention

31 March 2020

1 reference

12 December 2020

Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting.

1 reference

12 December 2020

Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

12 December 2020

10.1038/NRCARDIO.2011.128

Identifiers

DOI

1 reference

25 August 2017

1 reference